Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Caribou Biosciences (CRBU) Net Income towards Common Stockholders (2020 - 2025)

Historic Net Income towards Common Stockholders for Caribou Biosciences (CRBU) over the last 6 years, with Q3 2025 value amounting to -$29.4 million.

  • Caribou Biosciences' Net Income towards Common Stockholders rose 2311.31% to -$29.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$158.8 million, marking a year-over-year increase of 388.48%. This contributed to the annual value of -$149.1 million for FY2024, which is 4608.11% down from last year.
  • According to the latest figures from Q3 2025, Caribou Biosciences' Net Income towards Common Stockholders is -$29.4 million, which was up 2311.31% from -$47.6 million recorded in Q2 2025.
  • Caribou Biosciences' Net Income towards Common Stockholders' 5-year high stood at -$13.2 million during Q1 2021, with a 5-year trough of -$47.6 million in Q2 2025.
  • Moreover, its 5-year median value for Net Income towards Common Stockholders was -$30.6 million (2022), whereas its average is -$30.3 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first crashed by 66447.65% in 2021, then surged by 4485.81% in 2023.
  • Caribou Biosciences' Net Income towards Common Stockholders (Quarter) stood at -$18.5 million in 2021, then plummeted by 65.47% to -$30.6 million in 2022, then fell by 22.45% to -$37.4 million in 2023, then dropped by 3.83% to -$38.9 million in 2024, then increased by 24.37% to -$29.4 million in 2025.
  • Its Net Income towards Common Stockholders was -$29.4 million in Q3 2025, compared to -$47.6 million in Q2 2025 and -$42.9 million in Q1 2025.